US Bancorp DE Has $3.77 Million Position in The Cooper Companies, Inc. (NASDAQ:COO)

US Bancorp DE cut its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,007 shares of the medical device company’s stock after selling 1,416 shares during the quarter. US Bancorp DE’s holdings in Cooper Companies were worth $3,770,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Victory Capital Management Inc. boosted its stake in Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after purchasing an additional 737,726 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Cooper Companies in the 4th quarter valued at $691,000. Highland Capital Management LLC bought a new stake in Cooper Companies in the 4th quarter valued at $4,004,000. Caprock Group LLC bought a new stake in Cooper Companies in the 4th quarter valued at $282,000. Finally, Franklin Resources Inc. boosted its stake in Cooper Companies by 194.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after purchasing an additional 32,260 shares during the period. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Price Performance

Cooper Companies stock opened at $91.33 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The Cooper Companies, Inc. has a 52 week low of $84.76 and a 52 week high of $112.38. The stock has a market capitalization of $18.23 billion, a P/E ratio of 46.84, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The stock has a fifty day moving average of $92.56 and a 200-day moving average of $99.51.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the firm earned $0.87 EPS. Cooper Companies’s revenue was up 9.8% on a year-over-year basis. On average, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the subject of several recent research reports. StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Morgan Stanley cut their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research report on Friday, December 6th. Citigroup cut their target price on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Finally, Wells Fargo & Company upped their target price on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.22.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.